Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
By P. Home, Stuart J. Pocock, H. Beck-Nielsen, P. Curtis, R. Gomis, M. Hanefeld, N. Jones, M. Komajda, J. McMurray, Theodora S Temelkova-Kurktschiev. The Lancet, 2009
1,355 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/84417887ff0aa536edf989dbe5781e97a6ffd15b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Molecular Biology
Citations in the corpus
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2018, background): “However, these notable benefits must be balanced with safety concerns regarding fluid retention and congestive heart failure [136, 140, 141], weight gain [132, 136, 140–142], bone fracture [143, 144] and, possibly, bladder cancer [145].”
- Atherosclerosis: current pathogenesis and therapeutic options (2011, background): “Addition of rosiglitazone to glucose-lowering therapy failed to reduce cardiovascular events in patients with type 2 diabetes and, even worse, raised the risk of heart failur”
- Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials (2011, background): “and Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD)”
- Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. (2010, methodology): “No large, definitive CV outcomes trials have been conducted with rosiglitazone, although an open-label, noninferiority trial reported results in 2009 (RECORD [Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes]).(4) That study was limited by low event rates, which re”
- Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. (2009, positive): “The introduction of several new classes of medications within the past few years—especially incretin-based therapies such as incretin mimetics and dipeptidyl-peptidase-4 (DPP4) inhibitors—and the results from several recent largescale clinical trials—Action to Control Cardiovascular Risk in Diabetes”
- Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2013, background): “Although meta-analyses of smaller, underpowered studies suggested possible risk of MI with rosiglitazone (31,32), this has not been demonstrated in a larger randomized clinical trial (33,34).”
- Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). (2022, background): “However, these benefits must be balanced against possible side effects of fluid retention and congestive HF (196,197,202), weight gain (196–198,202,203), and bone fracture (204,205).”
- 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “Ambulatory IIb B (238, 240-244, 280) Additive risk stratification”
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “Pioglitazone may confer CVD benefits (103,105), whereas rosiglitazone has a neutral effect on CVD risk (106,107).”
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022, neutral): “However, these benefits must be balanced against possible side effects of fluid retention and congestive HF [196, 197, 202], weight gain [196–198, 202, 203] and bone fracture [204, 205].”
- Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations (2011, background): “Comparative Effectiveness for Long-Term Clinical Outcomes Although we included 2 additional large RCTs (23, 24) and 39 other studies since the 2007 review, studies were generally short (less than 1 year) and few events occurred, making estimates of risk very imprecise.”